Comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis.

This is the final version. Available from Springer via the DOI in this record. Data Availability: Anonymised individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com. Extracted data summaries are available upon request to the authors.INTRODUCTION: Few randomised controlled trials (RCTs) have directly compared long-acting muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) dual maintenance therapies for patients with chronic obstructive pulmonary disease (COPD). This systematic literature review and network meta-analysis (NMA) compared the efficacy of umeclidinium/vilanterol (UMEC/VI) versus other dual and mono-bronchodilator therapies in symptomatic patients with COPD. METHODS: A systematic literature review (October 2015-November 2020) was performed to identify RCTs ≥ 8 weeks long in adult patients with COPD that compared LAMA/LABA combinations against any long-acting bronchodilator-containing dual therapy or monotherapy. Data extracted on changes from baseline in trough forced expiratory volume in 1 s (FEV1), St George's Respiratory Questionnaire (SGRQ) total score, Transitional Dyspnoea Index (TDI) focal score, rescue medication use and moderate/severe exacerbation rate were analysed using an NMA in a frequentist framework. The primary comparison was at 24 weeks. Fixed effects model results are presented. RESULTS: The NMA included 69 full-length publications (including 10 GSK clinical study reports) reporting 49 studies. At 24 weeks, UMEC/VI provided statistically significant greater improvements in FEV1 versus all dual therapy and monotherapy comparators. UMEC/VI provided similar improvements in SGRQ total score compared with all other LAMA/LABAs, and significantly greater improvements versus UMEC 125 μg, glycopyrronium 50 μg, glycopyrronium 18 μg, tiotropium 18 μg and salmeterol 50 μg. UMEC/VI also provided significantly better outcomes versus some comparators for TDI focal score, rescue medication use, annualised moderate/severe exacerbation rate, and time to first moderate/severe exacerbation. CONCLUSION: UMEC/VI provided generally better outcomes compared with LAMA or LABA monotherapies, and consistent improvements in lung function (measured by change from baseline in trough FEV1 at 24 weeks) versus dual therapies. Treatment with UMEC/VI may improve outcomes for symptomatic patients with COPD compared with alternative maintenance treatments.GlaxoSmithKlei

Correction to: Comparative efficacy of Umeclidinium/Vilanterol versus other bronchodilators for the treatment of chronic obstructive pulmonary disease: A network meta-analysis.

This is the final version. Available from Springer via the DOI in this record. The authors regret to inform readers that the labels for the ‘treatment favour’ arrows were incorrectly labelled in Fig. 4. The ‘Favours UMEC/VI 62.5/25’ and ‘Favours comparator’ labels were appended to the wrong arrows and the corrected Fig. 4 is shown below. Please note that the data have not changed between versions